Management of thoracic endograft infection

R. Chiesa, Y. Tshomba, A. Kahlberg, E. M. Marone, E. Civilini, G. Coppi, D. Psacharopulo, G. Melissano

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Thoracic endovascular aortic repair (TEVAR) has emerged as a promising, less invasive alternative to conventional open surgery for the treatment of thoracic aortic pathology. Most surveillance after TEVAR concentrates on the technical aspects of the procedure, including endoleafc, device migration and endograft rupture; so far, the knowledge on endograft infectious complications is limited to anecdotal reports. Several etiopathogenetic factors may play a role in thoracic endograft infections (TEIs), including perioperative contamination, hematogenous seeding, and local bacterial translocation. Moreover, fistulization with the esophagus or the bronchial tree is a common mechanism of secondary TEI, and it represents a dramatic event requiring a multidiscipllnary management. Risk factors assessment and prevention have a key role in avoiding the development of new TEIs. When a TEI is established, treatment is demanding, and includes several medical therapies associated with various surgical options. Patients are usually severely compromised by sepsis, and in most cases they are considered unfit for surgery for general clinical conditions or local concerns. Thus, results of different therapeutic strategies for TEI are still burdened with very high morbidity and mortality. In this paper, we reviewed the English literature regarding the main strategies proposed for operative management of TEI, we reported and analyzed our personal series of 7 patients treated at our institution for TEI from 1999 to 2009, and we summarized results from the data collected during a recent Italian multicenter national survey, performed to investigate aortoesophageal and aorto-bronchial fistulae treated with TEVAR or developed following TEVAR.

Original languageEnglish
Pages (from-to)15-31
Number of pages17
JournalJournal of Cardiovascular Surgery
Volume51
Issue number1
Publication statusPublished - Feb 2010

Fingerprint

Thorax
Infection
Bronchial Fistula
Literature
Bacterial Translocation
Therapeutics
Esophagus
Thoracic Surgery
Rupture
Sepsis
Pathology
Morbidity
Equipment and Supplies
Mortality

Keywords

  • Aortic aneurysm thoracic
  • Fistula
  • Intraoperative complications
  • Sepsis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Chiesa, R., Tshomba, Y., Kahlberg, A., Marone, E. M., Civilini, E., Coppi, G., ... Melissano, G. (2010). Management of thoracic endograft infection. Journal of Cardiovascular Surgery, 51(1), 15-31.

Management of thoracic endograft infection. / Chiesa, R.; Tshomba, Y.; Kahlberg, A.; Marone, E. M.; Civilini, E.; Coppi, G.; Psacharopulo, D.; Melissano, G.

In: Journal of Cardiovascular Surgery, Vol. 51, No. 1, 02.2010, p. 15-31.

Research output: Contribution to journalArticle

Chiesa, R, Tshomba, Y, Kahlberg, A, Marone, EM, Civilini, E, Coppi, G, Psacharopulo, D & Melissano, G 2010, 'Management of thoracic endograft infection', Journal of Cardiovascular Surgery, vol. 51, no. 1, pp. 15-31.
Chiesa R, Tshomba Y, Kahlberg A, Marone EM, Civilini E, Coppi G et al. Management of thoracic endograft infection. Journal of Cardiovascular Surgery. 2010 Feb;51(1):15-31.
Chiesa, R. ; Tshomba, Y. ; Kahlberg, A. ; Marone, E. M. ; Civilini, E. ; Coppi, G. ; Psacharopulo, D. ; Melissano, G. / Management of thoracic endograft infection. In: Journal of Cardiovascular Surgery. 2010 ; Vol. 51, No. 1. pp. 15-31.
@article{7fe718c324014d38bcbf3084ae7c18ac,
title = "Management of thoracic endograft infection",
abstract = "Thoracic endovascular aortic repair (TEVAR) has emerged as a promising, less invasive alternative to conventional open surgery for the treatment of thoracic aortic pathology. Most surveillance after TEVAR concentrates on the technical aspects of the procedure, including endoleafc, device migration and endograft rupture; so far, the knowledge on endograft infectious complications is limited to anecdotal reports. Several etiopathogenetic factors may play a role in thoracic endograft infections (TEIs), including perioperative contamination, hematogenous seeding, and local bacterial translocation. Moreover, fistulization with the esophagus or the bronchial tree is a common mechanism of secondary TEI, and it represents a dramatic event requiring a multidiscipllnary management. Risk factors assessment and prevention have a key role in avoiding the development of new TEIs. When a TEI is established, treatment is demanding, and includes several medical therapies associated with various surgical options. Patients are usually severely compromised by sepsis, and in most cases they are considered unfit for surgery for general clinical conditions or local concerns. Thus, results of different therapeutic strategies for TEI are still burdened with very high morbidity and mortality. In this paper, we reviewed the English literature regarding the main strategies proposed for operative management of TEI, we reported and analyzed our personal series of 7 patients treated at our institution for TEI from 1999 to 2009, and we summarized results from the data collected during a recent Italian multicenter national survey, performed to investigate aortoesophageal and aorto-bronchial fistulae treated with TEVAR or developed following TEVAR.",
keywords = "Aortic aneurysm thoracic, Fistula, Intraoperative complications, Sepsis",
author = "R. Chiesa and Y. Tshomba and A. Kahlberg and Marone, {E. M.} and E. Civilini and G. Coppi and D. Psacharopulo and G. Melissano",
year = "2010",
month = "2",
language = "English",
volume = "51",
pages = "15--31",
journal = "Journal of Cardiovascular Surgery",
issn = "0021-9509",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Management of thoracic endograft infection

AU - Chiesa, R.

AU - Tshomba, Y.

AU - Kahlberg, A.

AU - Marone, E. M.

AU - Civilini, E.

AU - Coppi, G.

AU - Psacharopulo, D.

AU - Melissano, G.

PY - 2010/2

Y1 - 2010/2

N2 - Thoracic endovascular aortic repair (TEVAR) has emerged as a promising, less invasive alternative to conventional open surgery for the treatment of thoracic aortic pathology. Most surveillance after TEVAR concentrates on the technical aspects of the procedure, including endoleafc, device migration and endograft rupture; so far, the knowledge on endograft infectious complications is limited to anecdotal reports. Several etiopathogenetic factors may play a role in thoracic endograft infections (TEIs), including perioperative contamination, hematogenous seeding, and local bacterial translocation. Moreover, fistulization with the esophagus or the bronchial tree is a common mechanism of secondary TEI, and it represents a dramatic event requiring a multidiscipllnary management. Risk factors assessment and prevention have a key role in avoiding the development of new TEIs. When a TEI is established, treatment is demanding, and includes several medical therapies associated with various surgical options. Patients are usually severely compromised by sepsis, and in most cases they are considered unfit for surgery for general clinical conditions or local concerns. Thus, results of different therapeutic strategies for TEI are still burdened with very high morbidity and mortality. In this paper, we reviewed the English literature regarding the main strategies proposed for operative management of TEI, we reported and analyzed our personal series of 7 patients treated at our institution for TEI from 1999 to 2009, and we summarized results from the data collected during a recent Italian multicenter national survey, performed to investigate aortoesophageal and aorto-bronchial fistulae treated with TEVAR or developed following TEVAR.

AB - Thoracic endovascular aortic repair (TEVAR) has emerged as a promising, less invasive alternative to conventional open surgery for the treatment of thoracic aortic pathology. Most surveillance after TEVAR concentrates on the technical aspects of the procedure, including endoleafc, device migration and endograft rupture; so far, the knowledge on endograft infectious complications is limited to anecdotal reports. Several etiopathogenetic factors may play a role in thoracic endograft infections (TEIs), including perioperative contamination, hematogenous seeding, and local bacterial translocation. Moreover, fistulization with the esophagus or the bronchial tree is a common mechanism of secondary TEI, and it represents a dramatic event requiring a multidiscipllnary management. Risk factors assessment and prevention have a key role in avoiding the development of new TEIs. When a TEI is established, treatment is demanding, and includes several medical therapies associated with various surgical options. Patients are usually severely compromised by sepsis, and in most cases they are considered unfit for surgery for general clinical conditions or local concerns. Thus, results of different therapeutic strategies for TEI are still burdened with very high morbidity and mortality. In this paper, we reviewed the English literature regarding the main strategies proposed for operative management of TEI, we reported and analyzed our personal series of 7 patients treated at our institution for TEI from 1999 to 2009, and we summarized results from the data collected during a recent Italian multicenter national survey, performed to investigate aortoesophageal and aorto-bronchial fistulae treated with TEVAR or developed following TEVAR.

KW - Aortic aneurysm thoracic

KW - Fistula

KW - Intraoperative complications

KW - Sepsis

UR - http://www.scopus.com/inward/record.url?scp=77950655558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950655558&partnerID=8YFLogxK

M3 - Article

C2 - 20081759

AN - SCOPUS:77950655558

VL - 51

SP - 15

EP - 31

JO - Journal of Cardiovascular Surgery

JF - Journal of Cardiovascular Surgery

SN - 0021-9509

IS - 1

ER -